Seroprevalence of IgG antibodies against measles in adolescents and adults from Metropolitan Lima and Callao, Peru, 2024-2025
4 affiliations
- 1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru. Centro Nacional de Salud Pública Instituto Nacional de Salud Lima Peru
- 2Unidad de Intervenciones Estratégicas, Instituto Nacional de Salud, Lima, Peru. Unidad de Intervenciones Estratégicas Instituto Nacional de Salud Lima Peru
- 3Laboratorio de Referencia Nacional de Patología Clínica, Instituto Nacional de Salud, Lima, Peru. Laboratorio de Referencia Nacional de Patología Clínica Instituto Nacional de Salud Lima Peru
- 4Área de Sarampión y Rubéola, Laboratorio de Referencia Nacional de Virus Inmunoprevenibles, Instituto Nacional de Salud, Lima, Peru. Área de Sarampión y Rubéola Laboratorio de Referencia Nacional de Virus Inmunoprevenibles Instituto Nacional de Salud Lima Peru
Abstract
Objectives.: To estimate the seroprevalence of measles IgG antibodies in people aged 15 years or older residing in Lima Metropolitan and Callao, Peru, through secondary analysis of serum samples obtained from the National Institute of Health's Non-Communicable Diseases Surveillance between 2024 and 2025.
Materials and methods.: A descriptive, population-based, cross-sectional study that included 770 serum samples, in which the presence of measles IgG antibodies was determined using a commercial ELISA assay. Global seroprevalence was estimated and stratified by sex, age group, and origin.
Results.: After data expansion, 53.6% of the studied population corresponded to women. The global seroprevalence was 82.1% (95% CI: 78.6%-85.1%). Adults aged 20 to 29 years showed the lowest seroprevalence (55.6%), followed by adolescents aged 15 to 19 years (72.0%). Seroprevalence progressively increased with age and exceeded 95% in people aged 50 years or older. No significant differences were observed by sex or area of origin.
Conclusions.: Immunity gaps against measles are evident mainly in young adults, in a context of disease resurgence in the Americas and an ongoing outbreak in Peru. These findings highlight the value of seroprevalence studies to identify susceptible groups and guide public health interventions, such as targeted vaccination strategies, strengthening epidemiological surveillance, and information campaigns to reduce immunity gaps and contribute to maintaining measles elimination in Peru.
Related
- Seroprevalence of measles-specific IgM and IgG antibodies among children (0–12 years) with measles-like symptoms: a hospital-based cross-sectional study in Northeast Nigeria
- Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer
- Seroprevalence of varicella antibodies in unvaccinated children with nephrotic syndrome in disease remission.
- Seroprevalence of Japanese encephalitis virus and other flavivirus-specific antibodies among Australian blood donors following a novel epidemic spread of Japanese encephalitis virus: a cross-sectional study
- Positivity Rates and Serum Levels of Antibodies Against Histone H3 Lysine 9 and Its Lactylated Form in Rheumatoid Arthritis and Its Mimics
BibTeX
@article{vargasherrera2026seroprevalence,
title = {{Seroprevalence of IgG antibodies against measles in adolescents and adults from Metropolitan Lima and Callao, Peru, 2024-2025}},
author = {Natalia Vargas-Herrera and Margot Vidal-Anzardo and Chandel Farroñay-García and Nestor E. Cabezudo Pillpe and Roxana Ramírez-Salcedo and Edda Salamanca-Pacheco and Myriam Yasuda-Espinoza and Víctor Fiestas-Solórzano},
journal = {Revista Peruana de Medicina Experimental y Salud Publica},
year = {2026},
month = sep,
doi = {10.17843/rpmesp.2026.433.16877},
url = {https://doi.org/10.17843/rpmesp.2026.433.16877},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Seroprevalence of IgG antibodies against measles in adolescents and adults from Metropolitan Lima and Callao, Peru, 2024-2025
AU - Natalia Vargas-Herrera
AU - Margot Vidal-Anzardo
AU - Chandel Farroñay-García
AU - Nestor E. Cabezudo Pillpe
AU - Roxana Ramírez-Salcedo
AU - Edda Salamanca-Pacheco
AU - Myriam Yasuda-Espinoza
AU - Víctor Fiestas-Solórzano
PY - 2026
DA - 2026/09/17
JO - Revista Peruana de Medicina Experimental y Salud Publica
DO - 10.17843/rpmesp.2026.433.16877
UR - https://doi.org/10.17843/rpmesp.2026.433.16877
AB - Objectives.: To estimate the seroprevalence of measles IgG antibodies in people aged 15 years or older residing in Lima Metropolitan and Callao, Peru, through secondary analysis of serum samples obtained from the National Institute of Health's Non-Communicable Diseases Surveillance between 2024 and 2025. Materials and methods.: A descriptive, population-based, cross-sectional study that included 770 serum samples, in which the presence of measles IgG antibodies was determined using a commercial ELISA assay. Global seroprevalence was estimated and stratified by sex, age group, and origin. Results.: After data expansion, 53.6% of the studied population corresponded to women. The global seroprevalence was 82.1% (95% CI: 78.6%-85.1%). Adults aged 20 to 29 years showed the lowest seroprevalence (55.6%), followed by adolescents aged 15 to 19 years (72.0%). Seroprevalence progressively increased with age and exceeded 95% in people aged 50 years or older. No significant differences were observed by sex or area of origin. Conclusions.: Immunity gaps against measles are evident mainly in young adults, in a context of disease resurgence in the Americas and an ongoing outbreak in Peru. These findings highlight the value of seroprevalence studies to identify susceptible groups and guide public health interventions, such as targeted vaccination strategies, strengthening epidemiological surveillance, and information campaigns to reduce immunity gaps and contribute to maintaining measles elimination in Peru.
SN - 1726-4634
SN - 1726-4642
ER -